study – Bangkok News

ACN Newswire

Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

พฤษภาคม 13, 2022 LAWANclinical, dorzagliatin, nature, study, with

SHANGHAI, CHINA, May 13, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicin…

JCN Newswire

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

พฤษภาคม 10, 2022 PAKPAOalzheimer's, disease, lecanemab, study, with

TOKYO and CAMBRIDGE, Mass., May 10, 2022 – (JCN Newswire via SEAPRWire.com) – …

JCN Newswire

Joint Feasibility Study on the Commercialization of Sustainable Aviation Fuel

เมษายน 19, 2022 PAKPAOaviation, chain, international, study, with

TOKYO, Apr 19, 2022 – (JCN Newswire via SEAPRWire.com) – ENEOS Corporation and…

JCN Newswire

Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting

มีนาคม 22, 2022 PAKPAOcarriers, core, lecanemab, study, with

CAMBRIDGE, Mass., and TOKYO, Mar 22, 2022 – (JCN Newswire via SEAPRWire.com) –…

JCN Newswire

Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab

มีนาคม 4, 2022 PAKPAOclinical, eisai, lecanemab, potential, study

TOKYO, Mar 4, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Bi…

ACN Newswire

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

กุมภาพันธ์ 7, 2022 LAWANclinical, development, multiple, phase, study

HONG KONG, Feb 7, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience…

JCN Newswire

Eisai’s Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study

มกราคม 19, 2022 PAKPAOalzheimer's, clinical, disease, nexgen, study

TOKYO, Jan 19, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. annou…

JCN Newswire

Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium

มกราคม 17, 2022 PAKPAOcombination, merck, patients, study, with

TOKYO, Jan 17, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. annou…

JCN Newswire

Investigational Alzheimer’s Disease Therapy Lecanemab Granted FDA Fast Track Designation

ธันวาคม 24, 2021 PAKPAOclinical, early, phase, study, with

TOKYO, Dec 24, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and B…

JCN Newswire

Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer’s Disease (CTAD) Conference

พฤศจิกายน 12, 2021 PAKPAOalzheimer's, clinical, efficacy, lecanemab, study

TOKYO and CAMBRIDGE, Mass., Nov 12, 2021 – (JCN Newswire via SEAPRWire.com) – …

JCN Newswire

Eisai: Introduction of Plasma-based Biomarker Screening to Facilitate Identification of Subjects for Phase 3 Ahead 3-45 Trial Presented at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

พฤศจิกายน 12, 2021 PAKPAOamyloid, brain, clinical, elevated, study

TOKYO and CAMBRIDGE, Mass., Nov 12, 2021 – (JCN Newswire via SEAPRWire.com) – …

JCN Newswire

Eisai: DIAN-TU Selects Lecanemab as Background Anti-Amyloid Therapy in Clinical Trial Evaluating Investigational Therapy Targeting Tau for Dominantly Inherited Alzheimer’s Disease

พฤศจิกายน 9, 2021 PAKPAOalzheimer's, clinical, disease, inherited, study

TOKYO, Nov 9, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announ…

ACN Newswire

Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin

กันยายน 26, 2021 LAWANdiabetes, dream, patients, study, type

SHANGHAI, Sep 26, 2021 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (&#82…

ACN Newswire

SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases

กันยายน 17, 2021 LAWANclinical, everest, phase, study, with

HONG KONG, Sep 17, 2021 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScienc…

JCN Newswire

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401)

กรกฎาคม 30, 2021 PAKPAOcore, lecanemab, study, treatment, with

TOKYO, Jul 30, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and B…

JCN Newswire

Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021

กรกฎาคม 30, 2021 PAKPAOad-us, alzheimer's, disease, study, with

TOKYO, Jul 30, 2021 – (JCN Newswire via SEAPRWire.com) – Biogen (Nasdaq: BIIB)…

JCN Newswire

Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer’s Disease and Dementia at AAIC 2021

กรกฎาคม 21, 2021 PAKPAOalzheimer's, clinical, disease, study, will

TOKYO, Jul 21, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. annou…

JCN Newswire

Mitsubishi Motors (Thailand) Signs MoU with Eternity Grand Logistics to Do a Pilot Study on Commercial Usage of Compact EVs

กรกฎาคม 16, 2021 PAKPAOeternity, mitsubishi, motors, study, will

TOKYO, Jul 16, 2021 – (JCN Newswire via SEAPRWire.com) – Mitsubishi Motors Cor…

JCN Newswire

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Applications

พฤษภาคม 7, 2021 PAKPAOadvanced, carcinoma, endometrial, plus, study

TOKYO, May 7, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd.and Mer…

JCN Newswire

Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting

เมษายน 14, 2021 PAKPAOacademy, including, neurology, results, study

TOKYO, Apr 14, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. annou…

JCN Newswire

Signing of Memorandum of Understanding regarding CCS Joint Study for Clean Fuel Ammonia Production in Indonesia

มีนาคม 19, 2021 PAKPAOammonia, fuel, joint, production, study

TOKYO, Mar 19, 2021 – (JCN Newswire via SEAPRWire.com) – Japan Oil, Gas and Me…

ACN Newswire

Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

มีนาคม 12, 2021 PAKPAOat-301, avance, clinical, nasal, study

ADELAIDE, AU, Mar 12, 2021 – (ACN Newswire via SEAPRWire.com) – The leading Au…